307 filings
8-K
BDSI
Biodelivery Sciences International Inc
22 Mar 22
Termination of a Material Definitive Agreement
5:09pm
8-K/A
BDSI
Biodelivery Sciences International Inc
15 Feb 22
Entry into a Material Definitive Agreement
4:54pm
8-K
BDSI
Biodelivery Sciences International Inc
14 Feb 22
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
8:21am
8-K
BDSI
Biodelivery Sciences International Inc
20 Jan 22
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
8:05am
8-K
BDSI
Biodelivery Sciences International Inc
21 Dec 21
Regulation FD Disclosure
12:00am
8-K
mvarx
3 Nov 21
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
8:06am
8-K
1ue3fhh b0xmu0vagz9b
21 Oct 21
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
8:16am
8-K
ns46zzxg
27 Sep 21
Other Events
4:18pm
8-K
bq1drbhvvn439gaopv
21 Sep 21
Regulation FD Disclosure
5:03pm
8-K
d0xlf w0s
9 Sep 21
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada
9:26am
8-K
jht2qoyk1glal7s
4 Aug 21
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine
4:53pm
8-K
sawwj029akd3
4 Aug 21
BioDelivery Sciences Reports Second Quarter 2021 Results
8:07am
8-K
3yjww 7hwzg0lk
30 Jul 21
Submission of Matters to a Vote of Security Holders
4:03pm
8-K
vnl0pejas3 he
27 Jul 21
Other Events
2:23pm
8-K
orrl7o f3
7 Jul 21
Regulation FD Disclosure
8:31am
8-K
afxn8w6qc64f
6 May 21
BioDelivery Sciences Reports First Quarter 2021 Results
8:09am
8-K
8118oi
10 Mar 21
BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results
8:05am
8-K
lqeg5f
4 Dec 20
Departure of Directors or Certain Officers
5:13pm
8-K
k63wj cd3u
5 Nov 20
BioDelivery Sciences Reports Strong Q3 2020 Results
8:07am
8-K
y61jpsjp7
27 Oct 20
Departure of Directors or Certain Officers
4:09pm